João Pedro Ferreira

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker, Javed Butler, Gerasimos Filippatos et al. · New England Journal of Medicine · 2021 · 4.3K citations · Full text

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors, Christiane E. Angermann, John R. Teerlink et al. · Nature Medicine · 2022 · 814 citations · Full text

Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials

Muthiah Vaduganathan, Brian Claggett, Pardeep S. Jhund et al. · The Lancet · 2020 · 617 citations

Heart Failure, Cardiovascular Disease, Lifetime Benefits +10

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction

Milton Packer, Stefan D. Anker, Javed Butler et al. · Circulation · 2020 · 408 citations · Full text

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status

Stefan D. Anker, Javed Butler, Gerasimos Filippatos et al. · Circulation · 2020 · 332 citations · Full text